We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+0.99%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$7.04M
Cap. Flow
+$4.18M
Cap. Flow %
0.41%
Top 10 Hldgs %
43.95%
Holding
94
New
9
Increased
28
Reduced
9
Closed
24

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$20.2M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$17.1M
3
UAM
Universal American Corp
UAM
+$12.2M
4
RAD
Rite Aid Corporation
RAD
+$11.8M
5
CORI
Corium International, Inc.
CORI
+$10.6M

Top Sells

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$24.4M
2
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$21M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
4
OCR
OMNICARE INC
OCR
+$10.4M
5
MOH icon
Molina Healthcare
MOH
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 79.79%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAD
26
DELISTED
Rite Aid Corporation
RAD
$11.5M 1.12%
+80,000
New +$11.8M
LBMH
27
DELISTED
LIBERATOR MED HLDGS INC (NY)
LBMH
$11.5M 1.12%
3,058,644
– –
CARM
28
DELISTED
Carisma Therapeutics
CARM
$11.3M 1.1%
42,886
-211
-0.5% -$52.2K
TLGT
29
DELISTED
Teligent, Inc
TLGT
$11.2M 1.09%
210,000
+60,000
+40% +$3.07M
CORI
30
DELISTED
Corium International, Inc.
CORI
$10.9M 1.06%
+1,400,000
New +$10.6M
ELOS
31
DELISTED
Syneron Medical Ltd
ELOS
$10.4M 1.01%
1,005,221
– –
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$10.3M 1.01%
642,206
– –
CEMP
33
DELISTED
Cempra, Inc.
CEMP
$10.2M 1%
955,147
– –
ACGN
34
DELISTED
Aceragen Inc
ACGN
$10.2M 1%
25,950
+2,392
+10% +$987K
CRDC
35
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$10.1M 0.99%
887,499
+823,464
+1,286% +$8.35M
BKD icon
36
Brookdale Senior Living
BKD
$3.46B
$10.1M 0.99%
+303,000
New +$9.85M
OPCH icon
37
Option Care Health
OPCH
$3.31B
$9.58M 0.93%
287,221
+232,221
+422% +$6.98M
XNCR icon
38
Xencor
XNCR
$1.45B
$9M 0.88%
774,881
– –
SGNT
39
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$8.54M 0.83%
330,188
-50,000
-13% -$1.11M
QLTI
40
DELISTED
QLT Inc
QLTI
$8.21M 0.8%
1,328,392
+543,499
+69% +$3.01M
ATRS
41
DELISTED
Antares Pharma, Inc.
ATRS
$8.14M 0.79%
3,050,000
+750,000
+33% +$2.26M
TENX icon
42
Tenax Therapeutics
TENX
$388M
$8.03M 0.78%
62
+31
+100% +$4.78M
DRRX
43
DELISTED
DURECT Corp
DRRX
$8.02M 0.78%
440,450
– –
TNXP icon
44
Tonix Pharmaceuticals
TNXP
$169M
– –
0
– –
CCXI
45
DELISTED
ChemoCentryx, Inc.
CCXI
$6.14M 0.6%
1,050,000
– –
CPRX
46
DELISTED
Catalyst Pharmaceutical
CPRX
$6.07M 0.59%
+2,400,000
New +$5.13M
AUXL
47
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$6.02M 0.59%
300,000
-111,100
-27% -$2.55M
RXDX
48
DELISTED
Ignyta, Inc.
RXDX
$5.83M 0.57%
225,000
-416,700
-65% -$3.18M
CFN
49
DELISTED
CAREFUSION CORPORATION
CFN
$5.54M 0.54%
+125,000
New +$5.17M
POZN
50
DELISTED
POZEN INC
POZN
$5.5M 0.54%
659,730
-423,357
-39% -$3.64M
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Broadfin Capital held 94 positions worth $1.03B, down 0.68% from $1.03B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Broadfin Capital's Q2 2014 filing shows 9 new, 28 increased, 9 reduced and 24 closed positions. Its largest new stake was Rite Aid Corporation: 80,000 shares worth $11.5M. The largest sale was Lannett Company, Inc., an estimated $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 80% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2014 buy was Rite Aid Corporation: 80,000 shares worth $11.5M.
  • Broadfin Capital added most to AMAG Pharmaceuticals in Q2 2014, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q2 2014 reduction was Assertio, cutting an estimated $9.23M.
  • Broadfin Capital fully exited Lannett Company, Inc. in Q2 2014, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 44% of its $1.03B portfolio in Q2 2014.
  • Broadfin Capital opened 9 new positions and closed 24 in Q2 2014.
  • Broadfin Capital's portfolio value fell 0.68% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.